Clot, Clot, Who's There?

Explore the world of thrombosis and hemostasis with "Clot Clot, Who's There?", a thought-provoking podcast brought to you by Vasculearn Network in collaboration with the Thrombosis and Haemostasis Editors (Thieme).

Clot, Clot, Who's There? is a health podcast hosted by Unknown Host, with 18 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Unknown Host hosts Clot, Clot, Who's There?, a health show with 18 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #18

  Is Anticoagulation Still on Board? Rapid FXa Assessment

  Jul 31, 202629 min

  Your patient is bleeding or needs urgent surgery, but no one knows when the last DOAC dose was taken. Is there still enough factor Xa inhibitor on board to change what happens next? Join experts Alex Spyropoulos, Christopher Baugh, and Deborah Siegal as they discuss: • Why stabilization must come before laboratory confirmation • The limitations of routine coagulation tests • How to interpret drug-specific and heparin-calibrated anti-Xa assays • Practical pathways for major bleeding and urgent surgery • The future of rapid point-of-care testing Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations in thrombosis, hemostasis, and vascular medicine. 00:00: Assessing Residual Factor Xa Activity 03:41: Stabilize First, Test Second 08:56: Lab Testing: Options and Limitations 18:20: Major Bleeding vs. Urgent Surgery 21:54: The Future of Point-of-Care Testing Thank you to our sponsor, VarmX, for their generous support of this podcast episode. Check out the companion learning course, No Time To Wait: Urgent Situations in Patients on Factor Xa Inhibitors, here .

  ListenShow Notes
• 

  Episode #17

  Bleeding vs. Clotting: The Periprocedural Tightrope in Patients on Factor Xa Inhibitors

  Jul 31, 202623 min

  Factor Xa inhibitors have transformed anticoagulation, but urgent bleeding or surgery may require decisions before clinicians know when the last dose was taken or how much anticoagulant activity remains. Join experts Alex Spyropoulos, Eduardo Ramacciotti, and Preston Hewgley as they discuss: • Why residual factor Xa inhibitor activity matters in urgent care • How an unknown last dose complicates clinical decisions • Why bleeding risk persists despite DOAC advantages over warfarin • How to balance bleeding, thrombosis, and surgical urgency Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations in thrombosis, hemostasis, and vascular medicine. 00:00: Residual Factor Xa Activity: Why It Matters 01:38: Unknown Last Doses and Urgent Decisions 09:47: Major Bleeding and Urgent Surgery 14:03: Reversal, Treatment Delays, and Outcomes Thank you to our sponsor, VarmX, for their generous support of this podcast episode. Check out the companion learning course, No Time To Wait: Urgent Surgery in Patients on Factor Xa Inhibitors, here .

  ListenShow Notes
• 

  Episode #16

  The COBRRA Trial and the Questions that Remain

  Jun 30, 202622 min

  The COBRRA Trial and the Questions that Remain Clinicians have long relied on indirect comparisons when choosing between direct oral anticoagulants (DOACs) for VTE. The COBRRA trial changed that. Join experts Behnood Bikdeli, Lana Castellucci, and David Jiménez as they discuss: • The landmark COBRRA trial and its implications for VTE treatment • How bleeding risk, adherence, and patient preferences influence DOAC selection • When alternatives to apixaban may still be preferred • The challenges of conducting head-to-head anticoagulation trials • Global barriers to DOAC access and the next unanswered questions in the field Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations bridging science, practice, and global perspectives in thrombosis, hemostasis, and vascular medicine. 00:00: Introduction to COBRRA and the First Head-to-Head DOAC Comparison 03:58: Apixaban vs. Rivaroxaban: Key Findings and Clinical Implications 09:45: Adherence, Special Populations, and Choosing the Right DOAC 14:18: Why Did It Take So Long? Designing and Conducting the COBRRA Trial 19:05: Global Access, Reimbursement Challenges, and Real-World Use of DOACs 23:12: The Next Frontier: COBRRA-AF and Remaining Research Questions

  ListenShow Notes
• 

  Episode #15

  Thoracic Outlet Syndrome: Evidence vs. Experience

  Jun 1, 202627 minS0

  <p >When a young, otherwise healthy patient presents with an upper extremity DVT, venous thoracic outlet syndrome should be high on the differential—but the diagnosis is often delayed or missed.</p> <p >Join experts JoMarie Monzon, MSN, FNP-BC and Drs. Donna Bahroloomi, Ali Azizzadeh, and Vincent Jongkind as they discuss:</p> <p >Why venous thoracic outlet syndrome is frequently mistaken for musculoskeletal injury</p> <p >Diagnostic challenges and the role of imaging</p> <p >Current approaches to thrombolysis, decompression, venous reconstruction, and anticoagulation</p> <p >Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations br...

  ListenShow Notes
• 

  Episode #14

  Inside the Lab: Bypassing Factor Xa Inhibitors

  May 1, 202617 minS0

  <p >In urgent, high-stakes situations—like major bleeding or emergency surgery—how should clinicians assess coagulation in patients on factor Xa inhibitors? And more importantly, are we focusing on the right signal?</p> <p >Join global experts as they explore:</p> <p >Why traditional assays (PT/aPTT, anti-Xa) often fall short in critical decision-making</p> <p >The role of functional testing in assessing true hemostatic potential</p> <p >How VMX-C001, a novel bypassing agent, challenges conventional approaches to reversal and monitoring</p> <p >Be sure to read the VMX-C001 study discussed in the episode:<br /> https://www.rpthjournal.org/article/S247...

  ListenShow Notes

Recent guests on Clot, Clot, Who's There?. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.